Evidence map›Paper›PMID 35198074›Full record

ArticleTheranostics2022

Re-engineering the inner surface of ferritin nanocage enables dual drug payloads for synergistic tumor therapy.

Zhuoran Wang, Yue Zhao, Shuai Zhang, Xuehui Chen, Guoming Sun, Baoli Zhang, Bing Jiang, Yili Yang, Xiyun Yan, Kelong Fan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhuoran WangCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide, Pharmaceutical Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, P. R. China.
Yue ZhaoCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide, Pharmaceutical Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, P. R. China.
Shuai ZhangCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide, Pharmaceutical Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, P. R. China.
Xuehui ChenCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide, Pharmaceutical Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, P. R. China.
Guoming SunNanjing Nanozyme Tech Co., Ltd., Nanjing, 211500, P. R. China.
Baoli ZhangCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide, Pharmaceutical Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, P. R. China.
Bing JiangNanozyme Medical Center, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, P. R. China.
Yili YangChina Regional Research Center, International Center for Genetic Engineering and Biotechnology, Taizhou, 225312, P. R. China.
Xiyun YanCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide, Pharmaceutical Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, P. R. China.
Kelong FanCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide, Pharmaceutical Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, P. R. China.
University of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FerritinsGliomaApoferritinsCell Line, TumorDoxorubicinDrug CarriersDrug Delivery SystemsDrug LiberationEpirubicinHumansApoferritinsDoxorubicinDrug CarriersEpirubicinFerritinsdual drug payloadshydrophobic drugs loadinginner surface engineeringre-design of ferritin nanocagesynergistic tumor therapy

Identifiers

PMID35198074
PMCPMC8825595
OpenAlexW4210463100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.